Global Continuous Glucose Monitoring (CGM) Market
Continuous Glucose Monitoring (CGM) Market Overview
The global continuous glucose monitoring (CGM) market is projected to reach $16,574 million by 2025 from 2016 value of $830 million growing at a CAGR of 33.5% during 2017 - 2025.Continuous glucose monitor (CGM) system chiefly consists of three major components, namely sensors, transmitters & receivers and Insulin Pumps. However, in conventional CGM systems, insulin pumps were optional, whereas they are an integral part of modern CGMs. CGMs are more expensive than the conventional glucose monitoring systems. Technological innovation such as launch of artificial pancreas has taken diabetic care management to a next level. Recently, artificial pancrea got FDA approval. Thus, advancement in CGM systems makes possible early detection of hypoglycemia in an easy manner in comparison to infrequent point-of-care glucose meter measurements. However, there are few limitations associated with the CGMs, as they do not replace finger prick method for accurate readings, they require skill and training in diabetes management and they are not yet covered by majority of the insurance providers.
Currently CGMs are chiefly used in home settings, diagnosed centers and hospitals. Main use of CGMs are for continuously monitoring the glucose level irrespective of the location and its usage is almost hassle free and hence is comfortably used in home settings. Diagnostics center is another application area which is also gaining popularity due to increase in use in case studies so as to allow effective reporting methods of glucose levels. Currently, adoption of CGMs in the hospitals settings currently is not overwhelming however it is expected to gain a boost in next three to four years as it offers benefits in ICU medication such as:
The CGM systems need to be calibrated with a finger-stick (twice or thrice a day) to ensure improved accuracy. Patients thus require finger-sticks for calibration, and it is also recommended to use finger-stick measurements for checking hypoglycemia or hyperglycemia before taking corrective action.
To manage diabetes effectively, real-time continuous glucose monitoring is of utmost importance across all age groups. Continuous glucose monitoring system (CGMS) enables effective managing blood glucose levels by providing trend data as well as alarms for the fluctuations in glucose levels. Adult population (>14years) segment was the highest contributor to the global continuous glucose monitoring systems market.
Incidences of diabetes in children are increasing every year. Europe has highest prevalence of diabetes with type-1 diabetes around 129,000 with 20,000 new cases per year. Approximately half of the patients diagnosed with type-1 diabetes are children every year. Countries such as the U.K., the Russian Federation and France have highest number of Type-1 diabetic children patients.
In low income regions such as Africa and some of the Asian countries children diagnosed with type-1 diabetes often goes undiagnosed. Even if they are diagnosed in time they lack means to obtain insulin, syringes and monitoring devices and as a result they die. This is the main reason why we get to see lesser number of children patients with diabetes in such regions.
KEY BENEFITS
BY DEVICES
The global continuous glucose monitoring (CGM) market is projected to reach $16,574 million by 2025 from 2016 value of $830 million growing at a CAGR of 33.5% during 2017 - 2025.Continuous glucose monitor (CGM) system chiefly consists of three major components, namely sensors, transmitters & receivers and Insulin Pumps. However, in conventional CGM systems, insulin pumps were optional, whereas they are an integral part of modern CGMs. CGMs are more expensive than the conventional glucose monitoring systems. Technological innovation such as launch of artificial pancreas has taken diabetic care management to a next level. Recently, artificial pancrea got FDA approval. Thus, advancement in CGM systems makes possible early detection of hypoglycemia in an easy manner in comparison to infrequent point-of-care glucose meter measurements. However, there are few limitations associated with the CGMs, as they do not replace finger prick method for accurate readings, they require skill and training in diabetes management and they are not yet covered by majority of the insurance providers.
Currently CGMs are chiefly used in home settings, diagnosed centers and hospitals. Main use of CGMs are for continuously monitoring the glucose level irrespective of the location and its usage is almost hassle free and hence is comfortably used in home settings. Diagnostics center is another application area which is also gaining popularity due to increase in use in case studies so as to allow effective reporting methods of glucose levels. Currently, adoption of CGMs in the hospitals settings currently is not overwhelming however it is expected to gain a boost in next three to four years as it offers benefits in ICU medication such as:
- Detection of hypo-hyperglycemia
- Prediction of future glucose levels
- Instant feedback regarding treatment
- Improved patient comfort
- Assistance with insulin dose
- Less time
The CGM systems need to be calibrated with a finger-stick (twice or thrice a day) to ensure improved accuracy. Patients thus require finger-sticks for calibration, and it is also recommended to use finger-stick measurements for checking hypoglycemia or hyperglycemia before taking corrective action.
To manage diabetes effectively, real-time continuous glucose monitoring is of utmost importance across all age groups. Continuous glucose monitoring system (CGMS) enables effective managing blood glucose levels by providing trend data as well as alarms for the fluctuations in glucose levels. Adult population (>14years) segment was the highest contributor to the global continuous glucose monitoring systems market.
Incidences of diabetes in children are increasing every year. Europe has highest prevalence of diabetes with type-1 diabetes around 129,000 with 20,000 new cases per year. Approximately half of the patients diagnosed with type-1 diabetes are children every year. Countries such as the U.K., the Russian Federation and France have highest number of Type-1 diabetic children patients.
In low income regions such as Africa and some of the Asian countries children diagnosed with type-1 diabetes often goes undiagnosed. Even if they are diagnosed in time they lack means to obtain insulin, syringes and monitoring devices and as a result they die. This is the main reason why we get to see lesser number of children patients with diabetes in such regions.
KEY BENEFITS
- The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self-monitoring glucose devices, approval for artificial pancreas and many more.
- Market is forecast for the period 2017 - 2025 with market revenues for 1 historic years 2016.
- Identification and analysis of key pockets of investment for CGM manufacturers.
- Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market.
- Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario.
- The report identifies and profiles key market participants that would drive innovation in the CGM market.
BY DEVICES
- Transmitter and Receivers
- Sensors
- Insulin Pump
- Diagnostics/Clinics
- Hospitals
- Home Settings
- Adult Population (>14years)
- Child Population (≤14years)
- North America
- Europe
- Asia Pacific
- Row
- Medical Devices Manufacturers
- Research Institutions
- Healthcare Institutions
CHAPTER 1 INTRODUCTION
1.1 Objectives and Scope
1.2 Report Description
1.3 Key Benefits of the Report
1.4 Research Methodology
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 GLOBAL CONTINUOUS GLUCOSE MONITORS MARKET OVERVIEW
3.1 Healthcare Expenditure on Diabetes Worldwide
3.2 Type-1 Diabetics to Remain Key Target for CGM Market
3.2.1 Type-1 Diabetes
3.2.1.1 Type-1 Diabetes in Young People
3.2.2 Type-2 Diabetes
3.2.2.1 Type-2 Diabetes in Young People
3.2.3 Gestational Diabetes
3.2.4 Other Types of Diabetes
3.3 Market Intelligence
3.3.1 Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020
3.3.1.1 Fda Approval of Artificial Pancreas
3.3.1.2 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.3.1.3 Rise in Incidences of Diabetes Cases Globally
3.3.1.4 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.3.1.5 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.3.1.6 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.3.1.7 Strict Regulatory Impositions
3.3.1.8 Increase in Awareness Among Developing and Underdeveloped Economies
3.3.2 Top Three Winning Strategies in the Continuous Glucose Monitors Market
3.3.2.1 Global Market Players Positioning
3.3.3 Top Investment Pockets in Continuous Glucose Monitors Market
3.3.3.1 Continuous Glucose Monitors Market by Device
3.3.3.2 Continuous Glucose Monitors Market by Applications
3.3.3.3 Continuous Glucose Monitors Market by Geography
3.4 Regulations
3.5 Reimbursement Scenario
3.6 Market Dynamics
3.6.1 Drivers
3.6.1.1 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.6.1.2 FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System
3.6.1.3 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.6.1.4 Rise in Incidences of Diabetes Cases Globally
3.6.1.5 Increase in Awareness Among the Population in Developing and Underdeveloped Economies
3.6.2 Restraints
3.6.2.1 Strict Regulatory Impositions
3.6.2.2 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.6.2.3 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.6.3 Market Opportunity
3.6.3.1 Growth in Emerging Market
3.6.4 Winning Strategies for Mncs in Emerging Markets
3.6.4.1 Tailoring the Existing Products to the Local Market Needs
3.6.4.2 Adoption of a Proactive Hybrid Model Rather Than Distributor Management
3.6.4.3 Service Rendered Makes a Difference
3.6.4.4 Partnership and Acquisition Key to Enhance Reach and Market Position
3.6.4.5 Adopting An Emerging-Market Attitude
CHAPTER 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY DEVICES
4.1 Transmitter and Receivers
4.2 Sensors
4.2.1 Market Trend
4.2.1.1 Non-Invasive Glucose Sensors
4.2.1.2 Subcutaneous Sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional Technology Holter-Type Retrospective Sensors
4.2.1.4 Advanced Technology Real-Time Sensors
4.3 Insulin Pump
4.3.1 Advantages of Insulin Pump
4.3.2 Disadvantages of Insulin Pump
4.3.3 Market Trend
CHAPTER 5 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET - BY APPLICATION
5.1 Diagnostics/Clinics
5.2 Hospitals
5.3 Home Settings
5.4 Role of CGM in Private Practice
5.4.1 Team Members
5.4.2 Clinical Space
5.4.3 Scheduling
5.4.4 Keeping the Patients Informed
CHAPTER 6 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET BY AGE
6.1 Children and Teens
6.2 Youth
6.3 Middle Elderly and Aged
CHAPTER 7 CGM SYSTEMS MARKET BY GEOGRAPHY
7.1 North America
7.2 Europe
7.2.1 Financial Cost Incurred
7.3 Asia Pacific
7.4 Row
CHAPTER 8 COMPANY PROFILES
8.1 Medtronic Inc.
8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Business Performance
8.1.4 Strategic Moves and Developments
8.1.4.1 Principal Strategies: Product Launch
8.1.4.2 Secondary Strategies: Approval
8.1.4.3 Other Strategies: Collaboration
8.1.5 SWOT Analysis & Strategic Conclusions
8.2 Dexcom Inc.
8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Business Performance
8.2.4 Strategic Moves and Developments
8.2.4.1 Principal Strategies: Agreement/Partnership
8.2.4.2 Secondary Strategies: Acquisition
8.2.5 SWOT Analysis & Strategic Conclusions
8.3 Novo Nordisk
8.3.1 Company Profile
8.3.2 Company Snapshot
8.3.3 Strategic Moves and Developments
8.3.4 SWOT Analysis & Strategic Conclusions
8.4 Spring Health Solution Ltd
8.4.1 Company Profile
8.4.2 Company Snapshot
8.4.3 Strategic Moves and Developments
8.4.3.1 Principal Strategies
8.4.4 SWOT Analysis & Strategic Conclusions
8.5 Roche
8.5.1 Company Profile
8.5.2 Company Snapshot
8.5.3 Strategic Moves and Developments
8.5.4 SWOT Analysis & Strategic Conclusions
8.6 Animas Corporation
8.6.1 Company Profile
8.6.2 Company Snapshot
8.6.3 Strategic Moves and Developments
8.6.3.1 Principal Strategies
8.6.4 SWOT Analysis & Strategic Conclusions
8.7 Ypsomed AG
8.7.1 Company Profile
8.7.2 Company Snapshot
8.7.3 Strategic Moves and Developments
8.7.3.1 Principal Strategies: Product Expansion
8.7.3.2 Secondary Strategies: New Subsidiary
8.7.3.3 Other Strategies: Acquisition and Agreements
8.7.4 SWOT Analysis & Strategic Conclusions
8.8 Insulet Corporation
8.8.1 Company Profile
8.8.2 Company Snapshot
8.8.3 Strategic Moves and Developments
8.8.3.1 Principal Strategies
8.8.4 SWOT Analysis & Strategic Conclusions
1.1 Objectives and Scope
1.2 Report Description
1.3 Key Benefits of the Report
1.4 Research Methodology
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 GLOBAL CONTINUOUS GLUCOSE MONITORS MARKET OVERVIEW
3.1 Healthcare Expenditure on Diabetes Worldwide
3.2 Type-1 Diabetics to Remain Key Target for CGM Market
3.2.1 Type-1 Diabetes
3.2.1.1 Type-1 Diabetes in Young People
3.2.2 Type-2 Diabetes
3.2.2.1 Type-2 Diabetes in Young People
3.2.3 Gestational Diabetes
3.2.4 Other Types of Diabetes
3.3 Market Intelligence
3.3.1 Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020
3.3.1.1 Fda Approval of Artificial Pancreas
3.3.1.2 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.3.1.3 Rise in Incidences of Diabetes Cases Globally
3.3.1.4 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.3.1.5 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.3.1.6 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.3.1.7 Strict Regulatory Impositions
3.3.1.8 Increase in Awareness Among Developing and Underdeveloped Economies
3.3.2 Top Three Winning Strategies in the Continuous Glucose Monitors Market
3.3.2.1 Global Market Players Positioning
3.3.3 Top Investment Pockets in Continuous Glucose Monitors Market
3.3.3.1 Continuous Glucose Monitors Market by Device
3.3.3.2 Continuous Glucose Monitors Market by Applications
3.3.3.3 Continuous Glucose Monitors Market by Geography
3.4 Regulations
3.5 Reimbursement Scenario
3.6 Market Dynamics
3.6.1 Drivers
3.6.1.1 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.6.1.2 FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System
3.6.1.3 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.6.1.4 Rise in Incidences of Diabetes Cases Globally
3.6.1.5 Increase in Awareness Among the Population in Developing and Underdeveloped Economies
3.6.2 Restraints
3.6.2.1 Strict Regulatory Impositions
3.6.2.2 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.6.2.3 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.6.3 Market Opportunity
3.6.3.1 Growth in Emerging Market
3.6.4 Winning Strategies for Mncs in Emerging Markets
3.6.4.1 Tailoring the Existing Products to the Local Market Needs
3.6.4.2 Adoption of a Proactive Hybrid Model Rather Than Distributor Management
3.6.4.3 Service Rendered Makes a Difference
3.6.4.4 Partnership and Acquisition Key to Enhance Reach and Market Position
3.6.4.5 Adopting An Emerging-Market Attitude
CHAPTER 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY DEVICES
4.1 Transmitter and Receivers
4.2 Sensors
4.2.1 Market Trend
4.2.1.1 Non-Invasive Glucose Sensors
4.2.1.2 Subcutaneous Sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional Technology Holter-Type Retrospective Sensors
4.2.1.4 Advanced Technology Real-Time Sensors
4.3 Insulin Pump
4.3.1 Advantages of Insulin Pump
4.3.2 Disadvantages of Insulin Pump
4.3.3 Market Trend
CHAPTER 5 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET - BY APPLICATION
5.1 Diagnostics/Clinics
5.2 Hospitals
5.3 Home Settings
5.4 Role of CGM in Private Practice
5.4.1 Team Members
5.4.2 Clinical Space
5.4.3 Scheduling
5.4.4 Keeping the Patients Informed
CHAPTER 6 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET BY AGE
6.1 Children and Teens
6.2 Youth
6.3 Middle Elderly and Aged
CHAPTER 7 CGM SYSTEMS MARKET BY GEOGRAPHY
7.1 North America
7.2 Europe
7.2.1 Financial Cost Incurred
7.3 Asia Pacific
7.4 Row
CHAPTER 8 COMPANY PROFILES
8.1 Medtronic Inc.
8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Business Performance
8.1.4 Strategic Moves and Developments
8.1.4.1 Principal Strategies: Product Launch
8.1.4.2 Secondary Strategies: Approval
8.1.4.3 Other Strategies: Collaboration
8.1.5 SWOT Analysis & Strategic Conclusions
8.2 Dexcom Inc.
8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Business Performance
8.2.4 Strategic Moves and Developments
8.2.4.1 Principal Strategies: Agreement/Partnership
8.2.4.2 Secondary Strategies: Acquisition
8.2.5 SWOT Analysis & Strategic Conclusions
8.3 Novo Nordisk
8.3.1 Company Profile
8.3.2 Company Snapshot
8.3.3 Strategic Moves and Developments
8.3.4 SWOT Analysis & Strategic Conclusions
8.4 Spring Health Solution Ltd
8.4.1 Company Profile
8.4.2 Company Snapshot
8.4.3 Strategic Moves and Developments
8.4.3.1 Principal Strategies
8.4.4 SWOT Analysis & Strategic Conclusions
8.5 Roche
8.5.1 Company Profile
8.5.2 Company Snapshot
8.5.3 Strategic Moves and Developments
8.5.4 SWOT Analysis & Strategic Conclusions
8.6 Animas Corporation
8.6.1 Company Profile
8.6.2 Company Snapshot
8.6.3 Strategic Moves and Developments
8.6.3.1 Principal Strategies
8.6.4 SWOT Analysis & Strategic Conclusions
8.7 Ypsomed AG
8.7.1 Company Profile
8.7.2 Company Snapshot
8.7.3 Strategic Moves and Developments
8.7.3.1 Principal Strategies: Product Expansion
8.7.3.2 Secondary Strategies: New Subsidiary
8.7.3.3 Other Strategies: Acquisition and Agreements
8.7.4 SWOT Analysis & Strategic Conclusions
8.8 Insulet Corporation
8.8.1 Company Profile
8.8.2 Company Snapshot
8.8.3 Strategic Moves and Developments
8.8.3.1 Principal Strategies
8.8.4 SWOT Analysis & Strategic Conclusions
LIST OF TABLES
Table 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (AS OF MARCH 2013)
Table 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (AS OF MARCH 2013)
Table 3 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY PRODUCT CATEGORY, 2011-2020, ($MILLION)
Table 4 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 5 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS, 2011 - 2020, ($MILLION)
Table 8 GLOBAL CGM MARKET IN DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
Table 9 GLOBAL CGM MARKET IN HOSPITALS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
Table 10 GLOBAL CGM MARKET IN HOME SETTINGS, BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)
Table 12 TYPE-1 DIABETES (0-14 YEARS), 2013
Table 13 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2013 AND 2020
Table 14 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 15 THE PREVALENCE OF DIABETES IN THE ADULT POPULATION ACROSS THE U.K. IN 2011
Table 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
Table 17 PREVALENCE ESTIMATES OF DIABETES, 2013 & 2035
Table 18 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, AFRICA REGION
Table 19 MEDTRONIC BUSINESS SNAPSHOT
Table 20 DEXCOM INC. BUSINESS SNAPSHOT
Table 21 NOVA NORDISK BUSINESS SNAPSHOT
Table 22 SPRING HEALTH SOLUTION LTD BUSINESS SNAPSHOT
Table 23 ROCHE BUSINESS SNAPSHOT
Table 24 ANIMAS CORPORATION BUSINESS SNAPSHOT
Table 25 YPSOMED AG BUSINESS SNAPSHOT
Table 26 INSULET CORPORATION BUSINESS SNAPSHOT
Table 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (AS OF MARCH 2013)
Table 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (AS OF MARCH 2013)
Table 3 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY PRODUCT CATEGORY, 2011-2020, ($MILLION)
Table 4 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 5 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS, 2011 - 2020, ($MILLION)
Table 8 GLOBAL CGM MARKET IN DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
Table 9 GLOBAL CGM MARKET IN HOSPITALS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
Table 10 GLOBAL CGM MARKET IN HOME SETTINGS, BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)
Table 12 TYPE-1 DIABETES (0-14 YEARS), 2013
Table 13 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2013 AND 2020
Table 14 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS BY GEOGRAPHY, 2011 - 2020, ($MILLION)
Table 15 THE PREVALENCE OF DIABETES IN THE ADULT POPULATION ACROSS THE U.K. IN 2011
Table 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
Table 17 PREVALENCE ESTIMATES OF DIABETES, 2013 & 2035
Table 18 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, AFRICA REGION
Table 19 MEDTRONIC BUSINESS SNAPSHOT
Table 20 DEXCOM INC. BUSINESS SNAPSHOT
Table 21 NOVA NORDISK BUSINESS SNAPSHOT
Table 22 SPRING HEALTH SOLUTION LTD BUSINESS SNAPSHOT
Table 23 ROCHE BUSINESS SNAPSHOT
Table 24 ANIMAS CORPORATION BUSINESS SNAPSHOT
Table 25 YPSOMED AG BUSINESS SNAPSHOT
Table 26 INSULET CORPORATION BUSINESS SNAPSHOT
LIST OF FIGURES
Fig. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)
Fig. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, 20-79 YEARS ($BILLION)
Fig. 3 TREATMENT OF DIABETES, 2011
Fig. 4 SIMILARITIES IN CAUSE OF PRE-DIABETES AND TYPE-2 DIABETES
Fig. 5 CGM ADOPTION BY DIFFERENT TYPES OF DIABETES PATIENTS
Fig. 6 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)
Fig. 7 GLOBAL PREVALENCE OF TYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCE IN 2030
Fig. 8 TOP FACTORS IMPACTING CGM MARKET, 2013-2020
Fig. 9 TOP WINNING STRATEGY IN CGM MARKET, 2010 TO 2013 (SEPTEMBER)
Fig. 10 TOP WINNING STRATEGY IN CGM MARKET BY YEAR
Fig. 11 GLOBAL MARKET PLAYERS POSITIONING
Fig. 12 TOP INVESTMENT POCKETS IN CGM DEVICE MARKETS
Fig. 13 TOP INVESTMENT POCKETS IN CGM APPLICATION MARKETS
Fig. 14 TOP INVESTMENT POCKETS IN CGM GEOGRAPHY MARKETS
Fig. 15 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
Fig. 16 GDP PER CAPITA IN EMERGING ECONOMIES
Fig. 17 EMERGING MARKET CAPITALIZATION STRATEGIES
Fig. 18 GLOBAL CGM MARKET AMONG CHILDREN, 2011-2020, ($MILLION)
Fig. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)
Fig. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)
Fig. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)
Fig. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)
Fig. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)
Fig. 24 CASES OF DIABETES BY AGES IN NAC (1000S) (2013 E)
Fig. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)
Fig. 26 CASES OF DIABETES BY AGES IN EUROPE (1000S) (2013 E)
Fig. 27 ASIA PACIFIC CGM MARKET, 2013-2020, ($MILLION)
Fig. 28 TOP 10 COUNTRIES WITH DIABETES INCIDENCES 2013 AND 2035
Fig. 29 ROW CGM MARKET, 2013-2020, ($MILLION)
Fig. 30 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
Fig. 31 FINANCIAL REVENUES BY GEOGRAPHY (2013)
Fig. 32 FINANCIAL REVENUES BY GEOGRAPHY (2012)
Fig. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)
Fig. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, 20-79 YEARS ($BILLION)
Fig. 3 TREATMENT OF DIABETES, 2011
Fig. 4 SIMILARITIES IN CAUSE OF PRE-DIABETES AND TYPE-2 DIABETES
Fig. 5 CGM ADOPTION BY DIFFERENT TYPES OF DIABETES PATIENTS
Fig. 6 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)
Fig. 7 GLOBAL PREVALENCE OF TYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCE IN 2030
Fig. 8 TOP FACTORS IMPACTING CGM MARKET, 2013-2020
Fig. 9 TOP WINNING STRATEGY IN CGM MARKET, 2010 TO 2013 (SEPTEMBER)
Fig. 10 TOP WINNING STRATEGY IN CGM MARKET BY YEAR
Fig. 11 GLOBAL MARKET PLAYERS POSITIONING
Fig. 12 TOP INVESTMENT POCKETS IN CGM DEVICE MARKETS
Fig. 13 TOP INVESTMENT POCKETS IN CGM APPLICATION MARKETS
Fig. 14 TOP INVESTMENT POCKETS IN CGM GEOGRAPHY MARKETS
Fig. 15 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
Fig. 16 GDP PER CAPITA IN EMERGING ECONOMIES
Fig. 17 EMERGING MARKET CAPITALIZATION STRATEGIES
Fig. 18 GLOBAL CGM MARKET AMONG CHILDREN, 2011-2020, ($MILLION)
Fig. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)
Fig. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)
Fig. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)
Fig. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)
Fig. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)
Fig. 24 CASES OF DIABETES BY AGES IN NAC (1000S) (2013 E)
Fig. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)
Fig. 26 CASES OF DIABETES BY AGES IN EUROPE (1000S) (2013 E)
Fig. 27 ASIA PACIFIC CGM MARKET, 2013-2020, ($MILLION)
Fig. 28 TOP 10 COUNTRIES WITH DIABETES INCIDENCES 2013 AND 2035
Fig. 29 ROW CGM MARKET, 2013-2020, ($MILLION)
Fig. 30 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
Fig. 31 FINANCIAL REVENUES BY GEOGRAPHY (2013)
Fig. 32 FINANCIAL REVENUES BY GEOGRAPHY (2012)
